Ortho Development

Focus: Ortho Development is a newly founded (2024) medical device company specializing in orthopedic implants, publicly listed but with unclear commercial scale. The company's stated focus on ortho implants conflicts with a diverse pharmaceutical pipeline spanning hematology, oncology, neurology, and infectious diseases.

Hematology Oncology Neurology Infectious Diseases

Profile data last refreshed 22h ago · AI intelligence enriched 1w ago

Funding Stage

PUBLIC

Open Jobs

About Ortho Development

AI assessmentNot Hiring

No open roles listed right now. Follow Ortho Development to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

14 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Routine Total Hip Arthroplasty

Joint Diseases

N/A

Clinical Trials (1)

NCT03986918Survivorship and Patient Outcomes of Primary Total Hip Arthroplasty With the Ovation Hip System

N/A

Help build intelligence for Ortho Development

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage public company with potential for rapid scaling and equity upside if ortho implant commercialization succeeds
Diverse pipeline spanning 30+ programs across high-value therapeutic areas including oncology, hematology, and neurology
Ground-floor opportunity to build organizational infrastructure and establish long-term career trajectory in a newly public entity

Watch Out For

Zero active job openings despite public status raises questions about hiring plans, organizational readiness, and near-term growth capital
Fundamental strategic misalignment: company markets itself as ortho device specialist but pipeline contains no ortho-related programs—suggests unclear business model or mislabeled data
No employee count, financial data, or revenue disclosed; minimal active clinical trials (1 total) despite 30+ pipeline programs indicates early/dormant stage with execution risk

Generated by Claude from Ortho Development's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Total Hip Arthroplasty

Total Hip Replacement

N/A

Clinical Trials (1)

NCT04277416Survivorship and Effectiveness of the Ortho Development® Entrada™ Hip System for Total Hip Arthroplasty

N/A

Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

Esophagitis

N/A

Clinical Trials (1)

NCT00579410Comparison of Acid Reflux at Two Levels in the Esophagus Using the BRAVO Capsule

N/A

Balanced Knee System

Osteoarthritis, Knee

N/A

Clinical Trials (1)

NCT02362867Balanced Knee System Clinical Protocol for IRB Approval

N/A

JNJ-38877605

Neoplasms

PHASE_1

Clinical Trials (1)

NCT00651365A Safety and Dose-finding Study of JNJ-38877605 in Patients With Advanced or Refractory Solid Tumors.

Phase 1

epoetin alfa

Chronic Kidney Disease

PHASE_1

Clinical Trials (1)

NCT00641589A Study to Determine the Pharmacokinetic and Pharmacodynamic Profiles of PROCRIT (Epoetin Alfa) in Anemic Patients With Chronic Kidney Disease

Phase 1

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00210795A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2

PROCRIT

Anemia

PHASE_2

Clinical Trials (1)

NCT00210600Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving Chemotherapy

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00210743Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.

Phase 2

doxorubicin HCL liposome; bevacizumab; carboplatin

Ovarian Neoplasms

PHASE_2

Clinical Trials (1)

NCT00698451A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers

Phase 2

PROCRIT 40,000 IU QW

Peripheral Neuropathy, Chemotherapy-induced

PHASE_2

Clinical Trials (1)

NCT00267007A Study to Investigate the Neuroprotective Effect of PROCRIT (Epoetin Alfa) Versus Placebo in Cancer Patients Who Develop Chemotherapy-induced Peripheral Neuropathy

Phase 2

bortezomib; pegylated liposomal doxorubicin

Multiple Myeloma

PHASE_2

Clinical Trials (1)

NCT00706953A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Phase 2

Epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00338299Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced Anemia

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00306267A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving Chemotherapy

Phase 2

Epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00236678Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRIT

Phase 2

Epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00240734Treatment of Anemia in Diabetic Subjects With CKD

Phase 2

epoetin alfa

HIV Infections

PHASE_2

Clinical Trials (1)

NCT00528593Epoetin Alfa for HIV-Associated Neuropathy Trial

Phase 2

Epoetin alfa

Myelodysplastic Syndromes

PHASE_2

Clinical Trials (1)

NCT00446602A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

Phase 2

epoetin alfa

Neoplasms

PHASE_2

Clinical Trials (1)

NCT00386152A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving Chemotherapy

Phase 2

topiramate

Epilepsy, Absence

PHASE_2

Clinical Trials (1)

NCT00210574A Pilot Study of Topiramate in Childhood Absence Epilepsy

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00210756Pharmacokinetic/ Pharmacodynamic Study of Epoetin Alfa (PROCRIT) in Critically Ill Patients.

Phase 2

PROCRIT

Anemia

PHASE_2

Clinical Trials (1)

NCT00210626Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin Alfa

Phase 2

Epoetin Alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00388336PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00210834An Efficacy and Safety Study of Epoetin Alfa (PROCRIT) Initiated at 40,000 Units Every Week Versus 80,000 Units Every Two Weeks in Anemic Patients With Cancer Receiving Chemotherapy.

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00236405PROCRIT and Short-Term Outcomes in Orthopedic Surgery

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00228995A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic Anemia

Phase 2

Liposomal Doxorubicin

Breast Cancer

PHASE_2

Clinical Trials (1)

NCT00193037Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer

Phase 2

Epoetin alfa

Cancer

PHASE_2

Clinical Trials (1)

NCT00338416An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three Weeks

Phase 2

Epoetin Alfa

Renal Failure , Chronic

PHASE_2

Clinical Trials (1)

NCT00337935A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.

Phase 2

epoetin alfa

Anemia

PHASE_2

Clinical Trials (1)

NCT00246298A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected Patients

Phase 2

epoetin alfa

Chronic Kidney Disease

PHASE_2

Clinical Trials (1)

NCT00212875A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.

Phase 2

Epoetin alfa

Chemotherapy

PHASE_2

Clinical Trials (1)

NCT00337948An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four Weeks

Phase 2

levofloxacin

Pneumonia

PHASE_2_3

Clinical Trials (1)

NCT00257049A Study of the Safety and Effectiveness of Levofloxacin Compared With Ceftriaxone Sodium or Cefuroxime Axetil in the Treatment of Adults With Pneumonia

Phase 2/3

topiramate

Obesity

PHASE_2_3

Clinical Trials (1)

NCT00210808A Study of the Effectiveness and Safety of Topiramate in the Treatment of Moderate to Severe Binge-eating Disorder Associated With Obesity

Phase 2/3

levofloxacin

Skin Diseases, Infectious

PHASE_2_3

Clinical Trials (1)

NCT00257036A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Adults With Mild to Moderate Infections of the Skin and the Supportive Layers Beneath the Skin

Phase 2/3

levofloxacin

Bronchitis

PHASE_2_3

Clinical Trials (1)

NCT00257140A Study of the Safety and Effectiveness of Levofloxacin Compared With Cefaclor in the Treatment of Adults With Chronic Bronchitis Experiencing Rapid Onset of Worsening of Symptoms Caused by Bacteria

Phase 2/3

levofloxacin

Sinusitis

PHASE_3

Clinical Trials (1)

NCT00249210A Study of the Safety and Effectiveness of Levofloxacin Compared With Amoxicillin/Clavulanate Potassium in the Treatment of Adults With Rapid Onset of Severe Inflammation/Infection of the Sinuses

Phase 3

topiramate

Migraine

PHASE_3

Clinical Trials (1)

NCT00210860An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.

Phase 3

levofloxacin

Prostatitis

PHASE_3

Clinical Trials (1)

NCT00236808A Study to Evaluate the Safety and Effectiveness of Levofloxacin Compared With Ciprofloxacin in Patients With Chronic Bacterial Prostatitis

Phase 3

topiramate

Migraine

PHASE_3

Clinical Trials (1)

NCT00210912A Study of the Effectiveness and Safety of Topiramate Versus Placebo for Preventing Chronic Migraine Headaches

Phase 3

topiramate

Vascular Headaches

PHASE_3

Clinical Trials (1)

NCT00253175A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine

Phase 3

levofloxacin

Pneumonia

PHASE_3

Clinical Trials (1)

NCT00236821A Study to Compare the Safety and Effectiveness of 2 Doses of Levofloxacin Given for Different Time Periods in Patients With Pneumonia

Phase 3

levofloxacin; imipenem/cilastitin

Nosocomial Pneumonia

PHASE_3

Clinical Trials (1)

NCT00236834A Study of the Safety and Effectiveness of Levofloxacin Compared With Imipenem/Cilastatin in Patients With Pneumonia Acquired During Hospitalization

Phase 3

levofloxacin

Sinusitis

PHASE_3

Clinical Trials (1)

NCT00236522A Comparison of the Safety and Efficacy of Two Different Regimens of Levofloxacin in the Treatment of Acute Bacterial Sinusitis(Sinus Infection) in Adults.

Phase 3

Levofloxacin

Urinary Tract Infections

PHASE_3

Clinical Trials (1)

NCT00258089A Study of the Safety and Effectiveness of Oral Levofloxacin Compared With Oral Ciprofloxacin in the Treatment of Complicated Urinary Tract Infections

Phase 3

topiramate

Migraine

PHASE_3

Clinical Trials (1)

NCT00210873An Open Label Extension of a Study of Topiramate in Chronic Migraine.

Phase 3

levofloxacin, azithromycin, amoxicillin/clavulanate

Bronchitis

PHASE_3

Clinical Trials (1)

NCT00042718A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.

Phase 3

tramadol, acetaminophen

Diabetic Neuropathies

PHASE_3

Clinical Trials (1)

NCT00210847A Study Comparing the Effectiveness and Safety of Tramadol HCl/Acetaminophen Versus Placebo for the Treatment of Painful Neuropathy in Diabetic Patients

Phase 3

epoetin alfa

Anemia

PHASE_3

Clinical Trials (1)

NCT00211146A Study to Confirm the Safety and Efficacy of Epoetin Alfa (PROCRIT) Administered Perioperatively vs. the Standard of Care in Blood Conservation in Patients Undergoing Major Elective Spinal Surgery (SPINE Study)

Phase 3

Placebo

Myelodysplastic Syndromes

PHASE_3

Clinical Trials (1)

NCT00695396A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes at Risk for Transfusion

Phase 3